IIM
CADL icon

INTECH Investment Management’s Candel Therapeutics CADL Stock Holding History

INTECH Investment Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
12,601
+814
+7% +$6.15K ﹤0.01% 1897
2026
Q1 		$57.8K Sell
11,787
-6,039
-34% -$32.9K ﹤0.01% 1990
2025
Q4 		$101K Sell
17,826
-2,722
-13% -$14.6K ﹤0.01% 2153
2025
Q3 		$105K Sell
20,548
-3,323
-14% -$19.2K ﹤0.01% 2246
2025
Q2 		$121K Sell
23,871
-4,695
-16% -$24.2K ﹤0.01% 2247
2025
Q1 		$161K Buy
+28,566
New +$233K ﹤0.01% 2169

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

INTECH Investment Management's CADL Position: Q2 2026 in Review

INTECH Investment Management increased its Candel Therapeutics (CADL) stake by 6.9% in Q2 2026, buying an estimated $6.15K and bringing the position to 12,601 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1897.

INTECH Investment Management first reported a position in CADL in Q1 2025 and has held it in 6 quarters since. The position peaked at $161K in Q1 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • INTECH Investment Management held 12,601 shares of Candel Therapeutics worth $130K as of Q2 2026.
  • INTECH Investment Management bought 814 Candel Therapeutics shares in Q2 2026, an estimated $6.15K.
  • Candel Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1897 holding.
  • INTECH Investment Management first reported a position in Candel Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • INTECH Investment Management's Candel Therapeutics position peaked at $161K in Q1 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.